Female Urogenital Diseases: Clinical Trials

15215 completed, 4994 unknown, 3776 recruiting, 2285 terminated. 9188 Not applicable, 6031 Phase 2, 3853 Phase 1, 2892 Phase 3, 2037 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	9188	Completed 4514, Unknown 1647, Recruiting 1229, Not yet recruiting 572, Terminated 492, Active not recruiting 359, Withdrawn 264, Enrolling by invitation 89, Suspended 22
Phase 2	6031	Completed 2897, Terminated 796, Recruiting 745, Unknown 695, Active not recruiting 351, Withdrawn 260, Not yet recruiting 254, Suspended 19, Enrolling by invitation 14
Phase 1	3853	Completed 1993, Recruiting 519, Terminated 485, Unknown 328, Active not recruiting 237, Withdrawn 146, Not yet recruiting 115, Suspended 22, Enrolling by invitation 8
Phase 3	2892	Completed 1566, Unknown 368, Recruiting 292, Terminated 287, Active not recruiting 162, Withdrawn 116, Not yet recruiting 87, Suspended 8, Enrolling by invitation 6
Phase 4	2037	Completed 1084, Unknown 409, Terminated 179, Recruiting 145, Withdrawn 92, Not yet recruiting 74, Active not recruiting 38, Enrolling by invitation 9, Suspended 7
Early Phase 1	376	Completed 155, Unknown 61, Recruiting 47, Not yet recruiting 31, Terminated 28, Withdrawn 24, Active not recruiting 20, Enrolling by invitation 7, Suspended 3

Follow Female Urogenital Diseases: new trials by email Literature Review of Female Urogenital Diseases trials Research Report on Female Urogenital Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 serum creatinine assay - Acute Kidney Injury (Nontraumatic), Contrast-induced Nephropathy		Withdrawn	Maastricht University Medical Center		2097-11-01	2023-10-19
Time to Excretion of Contrast, a Maastricht Prospective Observational Study Contrast concentration in urine - Renal Insufficiency, Acute Kidney Injury		Withdrawn	Maastricht University Medical Center		2097-11-01	2023-10-19
Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast serum creatinine assay - Renal Insufficiency, Acute Kidney Injury		Withdrawn	Maastricht University Medical Center		2097-05-01	2023-10-19
Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications	Phase 2	Withdrawn	Institut Paoli-Calmettes		2032-01-01	2026-10-14
Antibiotics for Kidney Transplant Recipients Trimethoprim-Sulfamethoxazole (TMP-SMX), Usual Care - Kidney Transplant, Urinary Tract Infection(UTI)	Phase 4	Not yet recruiting	University of California, San Francisco	50	2028-10-01	2026-09-11
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer	Not applicable	Not yet recruiting	Chinese University of Hong Kong	60	2028-07-01	2026-10-28
MRI Technical Development and Applications in Kidney Disease Chronic Kidney Diseases, Kidney Transplantation		Not yet recruiting	University of Minnesota	180	2028-06-30	2026-04-13
Device for Bladder Control for Men With SCI Noninvasive electrical stimulation device to improve bladder control - Neurogenic Bladder	Phase 1 / Phase 2	Not yet recruiting	VA Office of Research and Development	12	2028-06-01	2026-06-25
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer	Not applicable	Not yet recruiting	Oncare Madrid	32	2028-05-01	2026-10-08
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders	Early Phase 1	Not yet recruiting	University of Valladolid	74	2028-02-01	2026-05-19
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy	Phase 2	Not yet recruiting	NovelMed Therapeutics	10	2028-02-01	2026-04-13
Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial. Esketamine, Placebo - Endometriosis	Phase 4	Not yet recruiting	Region Skane	1000	2028-01-01	2026-10-19
School-Based Bladder Health Intervention Bladder Health Education - Urinary Dysfunction, Lower Urinary Tract Symptoms	Not applicable	Withdrawn	Stanford University		2028-01-01	2026-05-07
Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury PRECISE-AKI Clinical Decision Support Tool - Acute Kidney Injury (AKI)	Not applicable	Not yet recruiting	VA Office of Research and Development	60	2028-01-01	2025-10-16
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome	Phase 2	Not yet recruiting	NovelMed Therapeutics	12	2027-11-01	2026-04-13
Veteran Centered Meal Intervention in Chronic Kidney Disease Medically tailored meals (MTMs) - Chronic Kidney Disease	Not applicable	Not yet recruiting	VA Office of Research and Development	100	2027-10-01	2026-09-03
Amino Acid Therapy Evaluating the Incidence of New-Onset AKI Amino Acid infusion, Lactated Ringer Solution - Acute Kidney Injury	Phase 2	Not yet recruiting	Children's Hospital Medical Center, Cincinnati	270	2027-10-01	2026-10-21
Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation Digital education outreach intervention for kidney transplant access and human guide, Digital education outreach intervention for kidney transplant access only (unguided) - End-Stage Renal Disease, Chronic Kidney Diseases	Not applicable	Not yet recruiting	State University of New York at Buffalo	550	2027-10-01	2026-10-20
Anti-Interleukin-6 (IL6) in Calciphylaxis Tocilizumab - Calciphylaxis	Phase 1	Not yet recruiting	Boston Medical Center	10	2027-09-01	2026-07-16

Showing 20 of 30524. Sign in to see all of them.

Narrower conditions

Ovarian Neoplasms (3262)  ·  Renal Insufficiency, Chronic (3078)  ·  Uterine Cervical Neoplasms (2247)  ·  Kidney Failure, Chronic (2001)  ·  Carcinoma, Renal Cell (1958)  ·  Urinary Bladder Neoplasms (1726)  ·  Acute Kidney Injury (1619)  ·  Endometrial Neoplasms (1392)  ·  Renal Insufficiency (1370)  ·  Breast Neoplasms (1001)  ·  Kidney Diseases (967)  ·  Kidney Neoplasms (956)  ·  Polycystic Ovary Syndrome (951)  ·  Urinary Incontinence (937)  ·  Neoplasms (916)

Broader conditions

Female Urogenital Diseases and Pregnancy Complications (30518)  ·  Urogenital Diseases (30484)  ·  Male Urogenital Diseases (20470)  ·  Urologic Diseases (19015)  ·  Kidney Diseases (12312)  ·  Pathological Conditions, Signs and Symptoms (12208)  ·  Genital Diseases (11825)  ·  Neoplasms (11448)  ·  Genital Diseases, Female (11052)  ·  Neoplasms by Site (10719)  ·  Urogenital Neoplasms (10529)  ·  Pathologic Processes (7912)  ·  Endocrine System Diseases (7035)  ·  Genital Neoplasms, Female (6550)

Interventions

Paclitaxel (586)  ·  Carboplatin (553)  ·  Cisplatin (445)  ·  pembrolizumab (396)  ·  Gemcitabine (361)  ·  Bevacizumab (347)  ·  Cyclophosphamide (258)  ·  Blood Specimen Collection (252)  ·  Nivolumab (242)  ·  Metformin (228)  ·  Surveys and Questionnaires (190)  ·  Magnetic Resonance Spectroscopy (173)  ·  Sunitinib (171)  ·  Standard of Care (170)  ·  Radiotherapy (167)

Sponsors

National Cancer Institute (NCI) (499)  ·  Assiut University (296)  ·  M.D. Anderson Cancer Center (277)  ·  AstraZeneca (207)  ·  Pfizer (206)  ·  Memorial Sloan Kettering Cancer Center (205)  ·  Mayo Clinic (193)  ·  Bayer (187)  ·  Assistance Publique - Hôpitaux de Paris (171)  ·  GlaxoSmithKline (163)  ·  Novartis Pharmaceuticals (160)  ·  National Taiwan University Hospital (150)  ·  Merck Sharp & Dohme LLC (149)  ·  Ain Shams University (146)  ·  Gynecologic Oncology Group (146)

Countries

United States (10948)  ·  China (2908)  ·  France (2329)  ·  Canada (1894)  ·  Italy (1741)  ·  United Kingdom (1622)  ·  Germany (1520)  ·  Spain (1505)  ·  Turkey (Türkiye) (1158)  ·  South Korea (1089)  ·  Egypt (985)  ·  Belgium (977)  ·  Netherlands (895)  ·  Australia (845)  ·  Denmark (820)

Top investigators

Lei Li, M.D. (40)

Results publications

PMID 37185961, PMID 40576086, PMID 39356039, PMID 36005278, PMID 37160401, PMID 39704322, PMID 38299639, PMID 37146227, PMID 35224730, PMID 36791280, PMID 32734597, PMID 35018639, PMID 37916745, PMID 39513526, PMID 36416787, PMID 37888839, PMID 34778952, PMID 37407274, PMID 38770818, PMID 41276263, PMID 34519356, PMID 33107592, PMID 34184246, PMID 37068952, PMID 37811598, PMID 37947276, PMID 38682786, PMID 31401903, PMID 33314078, PMID 35224732, PMID 38018702, PMID 32390133, PMID 33586138, PMID 35170751, PMID 37870148, PMID 38189593, PMID 39963952, PMID 27238653, PMID 28410911, PMID 33783815, PMID 37651553, PMID 38724717, PMID 39878152, PMID 33283264, PMID 34164803, PMID 36472416, PMID 33782940, PMID 37528520, PMID 39607014, PMID 40337980

NIH funding

2023 (177), 2016 (108), 2017 (108), 2018 (99), 2025 (95), U10CA027469 (95), 2019 (87), 2015 (76), 2014 (73), U10CA180868 (73), 2009 (63), 2008 (56), P30CA033572 (39), P30CA016672 (33), P30CA043703 (31)